FDA's love letter to itself
This article was originally published in Scrip
Executive Summary
The FDA sent itself a love letter on 16 July, which came in the form of a new report, in which regulators insisted that while the agency has worked to "transform the landscape" for the "final stage of drug development" – approval – those in science and industry who are doing the discovery, development and testing of new medicines have "not kept pace" in their progress.